The FDA granted Covidien plc (NYSE:COV) pre-market approval for its brain aneurysm treatment device.
The Mansfield, Mass.-based company designed its new endovascular device, aptly called the Pipeline, to redirect blood flow away from an aneurysm so an embolization can be performed.